Back to results
US 2004/0204407 A1Published application
5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
AssigneeSugen, Inc.
InventorsPeng Cho Tang, Congxin Liang, Todd Miller, Kenneth E. Lipson
Life of this patent
Estimating the term…
Abstract
The present invention relates to 5-sulfonamido substituted indolinones that modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.
Claims12
The compound of Formula (I):
- 139
- wherein
- R1 and R2 combine to form an optionally fused heterocyclic ring, which is optionally substituted by —O-alkyl, Br, Cl or F;
- R3, R4 and R5 are independently selected from the group consisting of H, lower alkyl optionally substituted with hydroxy and —(Y)0-1—Y1, wherein at least one of R3, R4 or R5 is —(Y)0-1—Y1;
- or R3 and R4 may combine to form a cyclic 6-membered alicyclic ring which may be substituted with one or more lower alkyl;
- Y is —CH2—, —CH2—CH2—, —CH2—CH2—CH2— or —C(O)NHR6—;
- Y1 is —C(O)OR′, —C(O)NR6R7 or —NR6R7, where R′ is H or lower alkyl;
- R6 and R7 are independently selected from the group consisting of H and lower alkyl optionally substituted by —NR8R9;
- or R6 and R7 may combine to form a heterocyclic ring which may include an additional heteroatom selected from the group consisting of N, O and S and which may be further substituted by optionally substituted alkyl or hydroxy;
- R8 and R9 are independently H and lower alkyl;
- or R8 and R9 may combine to form a heterocyclic ring which may include an additional heteroatom selected from the group consisting of N, O and S, which may be further substituted by alkyl;
- and pharmaceutically acceptable salts thereof.
9 more elements
A compound selected from the group consisting of Formula IV and VI:
- 140
- wherein
- R10-R11 are independently selected from the group consisting of H, lower alkyl, phenyl substituted with halo, thiazolyl and cycloalkyl;
- R12 is selected from the group consisting of —CH2—C(O)—X′—(CH2)n—Z, —CH2—Z,
- 141
- where D is O or N—CH3;
- X′ is NH, S, O or a bond;
- Z is a polar group selected from the group consisting of —C(O)OR13, —C(O)NR13R14, amino, alkylamino, dialkylamino, piperazinyl, pyrrolidinyl and morpholinyl, Z may be further substituted by —(CH2)0-1—Z1, where Z1 is a polar group selected from the group consisting of —C(O)OR13, —C(O)NR13R14, amino, alkylamino, dialkylamino, hydroxy, piperazinyl, pyrrolidinyl and morpholinyl;
- when Z is further substituted, R13 is not present;
- R13 and R14 are independently H and lower alkyl;
- n is 0-3;
- and
- Alk is lower alkyl of 1-4 carbons;
- and pharmaceutically acceptable salts thereof.
11 more elements
A compound selected from the group consisting of
- 5-(2,3-Dihydro-indole-1-sulfonyl)-3-[1-[3,5-dimethyl-4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-1,3-dihydro-indol-2-one;
- 2-{5-[5-[(3-Chloro-phenyl)-methyl-sulfamoyl]-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl}-N-(2-diethylamino-ethyl)-acetamide;
- 3-[1-[3-(2-Hydroxy-ethyl)-4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-5-(5-methoxy-2,3-dihydro-indole-1-sulfonyl)-1,3-dihydro-indol-2-one;
- 5-[5-(5-Methoxy-2,3-dihydro-indole-1-sulfonyl)-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide;
- 5-[5-(2,3-Dihydro-indole-1-sulfonyl)-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2-methyl-4-[3-(4-methyl-piperazin-1-yl)-propyl]-1H-pyrrole-3-carboxylic acid ethyl ester;
- 5-(2,3-Dihydro-indole-1-sulfonyl)-3-[1-[3-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-indol-2-yl]-meth-(Z)-ylidene]-1,3-dihydro-indol-2-one;
- (3Z)-N-(3-chlorophenyl)-3-{[3,5-dimethyl-4-(3-morpholin-4-ylpropyl)-1H-pyrrol-2-yl]methylene}-N-methyl-2-oxoindoline-5-sulfonamide;
- and
- (3Z)-5-(2,3-dihydro-1H-indol-1-ylsulfonyl)-3-{[3,5-dimethyl-4-(3-morpholin-4-ylpropyl)-1H-pyrrol-2-yl]methylene}-1,3-dihydro-2H-indol-2-one.
6 more elements
Dependencies are inferred from the claim text.